Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharma stock to overweight from equal weight.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
BioAge Labs' novel obesity treatment could boost the biotechnology company's stock, the Wall Street bank says.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
